Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) shares were down 13.8% on Wednesday . The company traded as low as $1.23 and last traded at $1.38. Approximately 4,437,037 shares were traded during mid-day trading, an increase of 30% from the average daily volume of 3,411,810 shares. The stock had previously closed at $1.60.

A number of research analysts have weighed in on IDXG shares. ValuEngine raised shares of Interpace Diagnostics Group from a “strong sell” rating to a “sell” rating in a research note on Monday. Maxim Group started coverage on shares of Interpace Diagnostics Group in a research note on Tuesday, August 15th. They issued a “buy” rating and a $5.00 price target on the stock.

The company’s market cap is $31.16 million. The firm’s 50-day moving average price is $1.21 and its 200 day moving average price is $1.75.

Interpace Diagnostics Group (NASDAQ:IDXG) last announced its quarterly earnings data on Thursday, August 10th. The business services provider reported ($0.65) EPS for the quarter. The company had revenue of $3.86 million for the quarter. Interpace Diagnostics Group had a negative return on equity of 32.06% and a negative net margin of 37.08%.

An institutional investor recently bought a new position in Interpace Diagnostics Group stock. Susquehanna International Group LLP bought a new position in Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) during the second quarter, according to its most recent filing with the SEC. The firm bought 718,076 shares of the business services provider’s stock, valued at approximately $646,000. Susquehanna International Group LLP owned approximately 3.84% of Interpace Diagnostics Group as of its most recent SEC filing. Institutional investors own 7.58% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Receive News & Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related companies with's FREE daily email newsletter.